AU2022336557A1 - Solid forms of bcl-2 inhibitors, method of preparation, and use thereof - Google Patents
Solid forms of bcl-2 inhibitors, method of preparation, and use thereof Download PDFInfo
- Publication number
- AU2022336557A1 AU2022336557A1 AU2022336557A AU2022336557A AU2022336557A1 AU 2022336557 A1 AU2022336557 A1 AU 2022336557A1 AU 2022336557 A AU2022336557 A AU 2022336557A AU 2022336557 A AU2022336557 A AU 2022336557A AU 2022336557 A1 AU2022336557 A1 AU 2022336557A1
- Authority
- AU
- Australia
- Prior art keywords
- crystalline form
- compound
- ray powder
- powder diffraction
- angle values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/115718 | 2021-08-31 | ||
| CN2021115718 | 2021-08-31 | ||
| PCT/CN2022/116084 WO2023030363A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022336557A1 true AU2022336557A1 (en) | 2024-03-21 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022336557A Pending AU2022336557A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (https=) |
| EP (1) | EP4396180A4 (https=) |
| JP (1) | JP2024530315A (https=) |
| KR (1) | KR20240054327A (https=) |
| CN (1) | CN118215660A (https=) |
| AU (1) | AU2022336557A1 (https=) |
| CA (1) | CA3230314A1 (https=) |
| IL (1) | IL311106A (https=) |
| MX (1) | MX2024002465A (https=) |
| TW (1) | TW202328125A (https=) |
| WO (1) | WO2023030363A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296582A (en) | 2020-04-15 | 2022-11-01 | Beigene Ltd | bcl-2 inhibitor |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2668180B1 (en) * | 2011-01-25 | 2018-08-01 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| SG11202009933WA (en) * | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 TW TW111132850A patent/TW202328125A/zh unknown
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024530315A (ja) | 2024-08-16 |
| WO2023030363A1 (en) | 2023-03-09 |
| CA3230314A1 (en) | 2023-03-09 |
| KR20240054327A (ko) | 2024-04-25 |
| CN118215660A (zh) | 2024-06-18 |
| EP4396180A4 (en) | 2025-07-09 |
| TW202328125A (zh) | 2023-07-16 |
| EP4396180A1 (en) | 2024-07-10 |
| US20240317743A1 (en) | 2024-09-26 |
| IL311106A (en) | 2024-04-01 |
| MX2024002465A (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10023577B2 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| US20240317743A1 (en) | Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof | |
| JP2015180679A (ja) | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 | |
| KR20260041111A (ko) | 아다그라시브 염의 결정질 형태 | |
| JP6447508B2 (ja) | ３−（イミダゾ［１，２−ｂ］ピリダジン−３−イルエチニル）−４−メチル−Ｎ−｛４−［（４−メチルピペラジン−１−イル）メチル］−３−（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形 | |
| KR20190020753A (ko) | 트리아졸로피리미딘 화합물의 결정질 형태 | |
| ES2874537T3 (es) | Sal oxalato de ruxolitinib | |
| ES2985767T3 (es) | Formas en estado sólido de rucaparib y de sales de rucaparib | |
| EP3205653B1 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| WO2023174400A1 (zh) | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 | |
| WO2024109871A1 (zh) | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 | |
| JP2014533719A (ja) | アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶 | |
| CN114075199A (zh) | Jak抑制剂化合物及其用途 | |
| EP4222148A1 (en) | Crystalline form of tegavivint, method of preparation, and use thereof | |
| EP2262786A2 (en) | Colchicine solid-state forms; methods of making; and methods of use thereof | |
| JP2022546861A (ja) | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 | |
| CN114026088A (zh) | Jak2抑制剂的结晶形式 | |
| WO2024188999A1 (en) | Crystalline form | |
| HK40106793A (zh) | Bcl-2抑制剂的固体形式、其制备方法及用途 | |
| EP3327007B1 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | |
| US20170029443A1 (en) | Polymorphic forms and co-crystals of a c-met inhibitor | |
| RU2792620C2 (ru) | Кристаллическая форма ингибитора parp-1 и способ ее получения | |
| WO2022224269A1 (en) | Co-crystals, salts and solid forms of niraparib | |
| CN116925083A (zh) | 5H-吡咯并[2,3-b]吡嗪衍生物的多晶型形式，制备方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BEONE MEDICINES I GMBH Free format text: FORMER APPLICANT(S): BEIGENE, LTD.; BEIGENE SWITZERLAND GMBH Owner name: BEIGENE SWITZERLAND GMBH Free format text: FORMER APPLICANT(S): BEIGENE, LTD.; BEIGENE SWITZERLAND GMBH |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO BEONE MEDICINES I GMBH |